New York State Common Retirement Fund acquired a new position in shares of Adicet Bio, Inc. (NASDAQ:ACET) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 17,900 shares of the company’s stock, valued at approximately $184,000.
A number of other institutional investors have also recently modified their holdings of the business. Millennium Management LLC grew its stake in Adicet Bio by 715.5% during the first quarter. Millennium Management LLC now owns 180,041 shares of the company’s stock worth $2,355,000 after buying an additional 157,963 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Adicet Bio during the first quarter worth about $13,709,000. D. E. Shaw & Co. Inc. grew its stake in Adicet Bio by 32.5% during the first quarter. D. E. Shaw & Co. Inc. now owns 32,486 shares of the company’s stock worth $425,000 after buying an additional 7,969 shares during the last quarter. Orbimed Advisors LLC lifted its position in shares of Adicet Bio by 7.8% during the first quarter. Orbimed Advisors LLC now owns 7,232,856 shares of the company’s stock worth $94,606,000 after purchasing an additional 524,349 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of Adicet Bio during the first quarter worth approximately $355,000. 66.67% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:ACET opened at $6.89 on Tuesday. Adicet Bio, Inc. has a 52 week low of $6.25 and a 52 week high of $18.89. The company has a market capitalization of $219.39 million, a PE ratio of -1.54 and a beta of 2.42. The company has a 50 day moving average price of $7.55 and a two-hundred day moving average price of $10.93.
A number of equities analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Adicet Bio from a “buy” rating to a “hold” rating in a research report on Friday. Jonestrading reiterated a “buy” rating and set a $33.00 target price on shares of Adicet Bio in a research report on Tuesday, August 24th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Adicet Bio currently has a consensus rating of “Buy” and an average target price of $26.39.
Adicet Bio Company Profile
Adicet Bio, Inc is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
Further Reading: What is the Fibonacci sequence?
Want to see what other hedge funds are holding ACET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adicet Bio, Inc. (NASDAQ:ACET).
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.